Blue Jet Healthcare First Quarter 2025 Earnings: Revenues Disappoint

Blue Jet Healthcare (NSE:BLUEJET) First Quarter 2025 Results

Key Financial Results

• Revenue: ₹1.72b (down 4.4% from 1Q 2024).
• Net income: ₹377.8m (down 14% from 1Q 2024).
• Profit margin: 22% (down from 25% in 1Q 2024). The decrease in margin was driven by lower revenue.
• EPS: ₹2.18 (down from ₹2.54 in 1Q 2024).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Blue Jet Healthcare Revenues Disappoint

Revenue missed analyst estimates by 13%. Earnings per share (EPS) was mostly in line with analyst estimates.

Looking ahead, revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India.

Performance of the Indian Pharmaceuticals industry.

The company's shares are up 5.9% from a week ago.

Valuation

Following the latest earnings results, Blue Jet Healthcare may be overvalued based on 6 different valuation benchmarks we assess. Click here to view our comprehensive analysis and gain insights into the stock's investment prospects.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com